Literature DB >> 9566108

Limitations of randomized controlled clinical trials to depict accurately long-term outcomes in rheumatoid arthritis.

T Pincus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9566108     DOI： 10.1007/s003930050059

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  4 in total

1.  Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

Authors:  R F van Vollenhoven; S Brannemark; L Klareskog
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

2.  Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.

Authors:  P Sidiropoulos; G Bertsias; H D Kritikos; H Kouroumali; K Voudouris; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

3.  Clinical research quo vadis? Trends in reporting of clinical trials and observational study designs over two decades.

Authors:  Moritz C Wyler von Ballmoos; James H Ware; Bernhard Haring
Journal:  J Clin Med Res       Date:  2015-04-08

4.  Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious.

Authors:  Ronald F van Vollenhoven; Sofia Ernestam; Anders Harju; Johan Bratt; Lars Klareskog
Journal:  Arthritis Res Ther       Date:  2003-10-01       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.